Syncom Formulations (India) Ltd

Despite a broader market rebound, Syncom Formulations (India) Ltd has succumbed to selling pressure, hitting a fresh 52-week low of Rs 10.45 on 30 Mar 2026. The stock’s recent decline contrasts sharply with the market’s tentative recovery, underscoring company-specific challenges that continue to weigh on investor sentiment.

Syncom Formulations (India) Ltd’s stock price declined sharply on 27 Mar 2026, hitting a new 52-week low of Rs.10.97. This marks a significant downturn for the pharmaceutical company amid broader market weakness and persistent challenges reflected in its financial and technical indicators.

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

While the broader market showed signs of recovery, Syncom Formulations (India) Ltd slipped to a fresh 52-week low of Rs 11.05 on 24 Mar 2026, extending a downward trajectory that has seen the stock lose nearly 38% over the past year.

Syncom Formulations (India) Ltd’s stock price declined sharply to a new 52-week low of Rs.11.28 on 23 March 2026, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector amid broader market weakness.

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO. This rating was last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Syncom Formulations (India) Ltd is rated Sell by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Syncom Formulations (India) Ltd has touched a new 52-week low of Rs.11.36 today, marking a significant decline in its stock price amid ongoing downward momentum. The pharmaceutical company’s shares have underperformed both its sector and the broader market, reflecting persistent challenges in its financial performance and market positioning.

Syncom Formulations (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 February 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Syncom Formulations (India) Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The pharmaceutical company’s shares have declined by 4.04% recently, reflecting growing investor caution amid deteriorating technical parameters and a downgrade in its Mojo Grade from Hold to Sell.

Syncom Formulations (India) Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from bearish to mildly bearish trends. Despite a modest daily gain of 1.03%, the stock’s overall technical profile remains cautious, reflecting mixed signals from MACD, RSI, moving averages, and other momentum oscillators. Investors in the Pharmaceuticals & Biotechnology sector should carefully analyse these developments as the stock navigates a challenging market environment.

Syncom Formulations (India) Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish territory. The company’s stock price has declined by 3.28% recently, reflecting growing investor caution amid mixed signals from moving averages, MACD, and other technical parameters.

Syncom Formulations (India) Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹1,321 crores, reported a net profit of ₹18.91 crores for Q3 FY26 (October-December 2025), marking a robust 45.46% year-on-year growth but facing sequential revenue headwinds. The stock, currently trading at ₹14.25, has declined 21.10% over the past year, significantly underperforming the Sensex's 9.85% gain and the broader pharmaceuticals sector's 6.53% return.

Syncom Formulations (India) Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators, financial trends, valuation metrics, and overall quality. This shift comes amid a backdrop of mixed long-term growth but encouraging recent quarterly results and a stabilising technical outlook, signalling cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.

Syncom Formulations (India) Ltd has exhibited a notable shift in its technical momentum, moving from a bearish stance towards a more cautiously optimistic outlook. Following a 6.13% surge in daily price and an upgrade in its Mojo Grade from Sell to Hold, the pharmaceutical and biotechnology company’s technical indicators reveal a complex but improving picture amid mixed signals from key momentum and trend metrics.

Syncom Formulations (India) Ltd commenced trading on 3 Feb 2026 with a notable gap up, opening 5.0% higher than its previous close, reflecting a strong start and positive sentiment in the Pharmaceuticals & Biotechnology sector.